Cannabis in Dentistry: What the Evidence Really Shows

Cannabis in dentistry is increasingly discussed in clinical care, but the evidence remains early and uneven. This review maps where cannabinoids may plausibly influence pain, inflammation, and anxiety, while also highlighting where the science simply does not yet support clinical conclusions.

What This Study Teaches Us

This paper is a narrative review synthesizing pharmacologic mechanisms, preclinical findings, and limited human evidence. It identifies biologically plausible roles for cannabinoids in dental care, particularly in pain modulation, inflammatory pathways, and anxiety reduction.

However, these potential benefits are largely derived from mechanistic reasoning and extrapolation rather than controlled clinical trials in dental populations. The absence of standardized dosing, formulation clarity, and procedural guidance limits clinical applicability.

The most meaningful contribution of this paper is not proof of efficacy, but a clear framing of how early this field remains.

Why This Matters

For the Public: Patients often experience real symptom relief with cannabis, but that does not necessarily translate into proven benefit in dental care, and may come with oral health risks.

For Clinicians: Cannabis use is common but inconsistently disclosed. Understanding interactions, perioperative implications, and oral effects is increasingly necessary for safe practice.

For Research and Policy: The gap between widespread use and limited evidence underscores the need for randomized trials, dosing standards, and clinical guidelines.

What This Paper Looked At

This paper is a narrative review that synthesizes multiple layers of evidence, including cannabinoid pharmacology, endocannabinoid system signaling, preclinical data, and limited human observations. It explores how cannabinoids may influence nociception, inflammatory cascades, and neurobehavioral responses relevant to dental care.

The review also examines potential clinical scenarios such as orofacial pain, procedural anxiety, and inflammatory oral conditions, while outlining known adverse effects including dry mouth, periodontal implications, and possible drug interactions. Importantly, the scope is broad and conceptual rather than narrowly defined, and the paper does not present new experimental data, standardized patient populations, or controlled clinical comparisons.

As such, the paper functions more as a framework for future investigation than as a guide for clinical implementation.

What the Paper Found

The authors identify several biologically plausible mechanisms through which cannabinoids could influence dental care. Activation of cannabinoid receptors within the endocannabinoid system may modulate pain perception through central and peripheral pathways, reduce inflammatory signaling, and alter stress responses that contribute to procedural anxiety.

These mechanisms create a theoretical rationale for potential use in conditions such as acute dental pain, temporomandibular disorders, and anxiety surrounding dental procedures. However, these proposed benefits are largely extrapolated from non-dental studies or preclinical models rather than demonstrated in controlled dental populations.

In parallel, the paper highlights consistent concerns associated with cannabis exposure. Xerostomia may increase caries risk, periodontal disease associations have been observed in some populations, and altered immune or healing responses may affect post-procedural recovery. Additionally, interactions with commonly used medications in dentistry, including sedatives and anesthetics, introduce further complexity.

Taken together, the findings suggest a field defined by potential rather than proof.

How Strong Is This Evidence?

This is low-tier evidence. Narrative reviews do not follow systematic inclusion criteria, do not quantitatively synthesize results, and are inherently vulnerable to selection bias. They are useful for organizing concepts and identifying research gaps, but they cannot establish causality or estimate clinical effect size.

The absence of randomized controlled trials in dental populations is a critical limitation. Without controlled comparisons, standardized dosing, and clearly defined outcomes, it is not possible to determine whether cannabinoids provide meaningful benefit beyond placebo or existing therapies.

At best, this paper should be interpreted as an early-stage conceptual overview rather than a clinically actionable evidence base.

Where This Paper Deserves Skepticism

A major limitation is the heavy reliance on mechanistic reasoning. While cannabinoid receptor activity and endocannabinoid signaling are well described, translating these pathways into predictable clinical outcomes is not straightforward. Biological plausibility does not reliably predict therapeutic efficacy.

Much of the cited evidence originates from animal models or non-dental clinical contexts, which may not reflect the unique physiological and procedural environment of dental care. Pain types, tissue characteristics, and procedural variables differ substantially from other medical domains.

Additionally, outcome measures such as pain and anxiety are inherently variable and influenced by expectation, context, and patient perception. Without standardized measurement and controlled comparison to established treatments, claims of benefit remain uncertain.

The review also does not sufficiently address heterogeneity in cannabinoid formulations, dosing strategies, or routes of administration, all of which significantly affect clinical outcomes.

What This Paper Does Not Show

This paper does not demonstrate clinical efficacy in dental patients. It does not establish whether cannabinoids improve outcomes compared to standard dental therapies, nor does it define optimal dosing, timing, or product selection for specific procedures or conditions.

It does not provide guidance on perioperative management, including how cannabis use may influence anesthesia requirements, bleeding risk, or recovery trajectories. It also does not clarify long-term safety within dental populations or repeated procedural contexts.

Importantly, it does not resolve whether observed associations between cannabis use and oral health outcomes are causal, confounded, or context-dependent.

How This Fits With the Broader Clinical Conversation

This paper reflects a broader pattern seen across cannabinoid research: a strong and often compelling biological foundation paired with a relatively underdeveloped clinical evidence base. The endocannabinoid system is deeply involved in pain, inflammation, and stress regulation, making it an attractive target for therapeutic exploration.

However, across many areas of medicine, including pain management and mental health, translation from mechanism to reliable clinical practice has been inconsistent. Dentistry appears to be following a similar trajectory, with growing interest and patient use outpacing the development of rigorous clinical data.

This mismatch creates a landscape where clinicians must navigate patient experiences, emerging science, and incomplete evidence simultaneously.

Dr. Caplan’s Take

The signal here is not that cannabis works in dentistry, but that it might. That distinction matters. The biology is interesting and potentially meaningful, but the clinical translation is not yet defined. In the absence of clear protocols, dosing frameworks, and outcome data, confidence should remain limited. The responsible posture is not dismissal, but disciplined restraint.

What a Careful Reader Should Take Away

Cannabis in dentistry is best understood as an emerging hypothesis rather than an established intervention. The science suggests possible pathways of benefit, but the evidence required to support routine clinical use is not yet in place.

For patients, this means distinguishing personal experience from proven efficacy. For clinicians, it means recognizing cannabis use as relevant to care while avoiding overinterpretation of its benefits.

Curiosity is warranted. Adoption is not yet justified. The appropriate stance is thoughtful engagement paired with clear recognition of uncertainty.

Frequently Asked Questions

Is cannabis effective for dental pain? Evidence is limited and not definitive.

Can CBD reduce dental anxiety? Possibly, but data are early.

Does cannabis harm oral health? It may increase risks like dry mouth and periodontal disease.

Are drug interactions a concern? Yes, especially via CYP450 metabolism.

Is cannabis safer than opioids? Not established in dental care.

Should dentists recommend cannabis? Only cautiously and case-by-case.

Can cannabis affect anesthesia? Chronic use may alter requirements.

Is pediatric use supported? Evidence is minimal.

What is the biggest limitation? Lack of randomized trials.

What is needed next? Controlled clinical studies.